Get the Stockscreener App
35.20
3.53%
1.20
Pre-market:
35.90
0.70
+1.99%
Harrow Inc stock is traded at $35.20, with a volume of 511.27K.
It is up +3.53% in the last 24 hours and down -33.31% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
See More
Previous Close:
$34.00
Open:
$33.77
24h Volume:
511.27K
Relative Volume:
0.71
Market Cap:
$1.31B
Revenue:
$272.30M
Net Income/Loss:
$-5.14M
P/E Ratio:
-215.29
EPS:
-0.1635
Net Cash Flow:
$42.76M
1W Performance:
-0.09%
1M Performance:
-33.31%
6M Performance:
-26.48%
1Y Performance:
+17.33%
1-Day Range:
$33.60
$35.59
1-Week Range:
$33.02
$35.61
52-Week Range:
$20.85
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
35.20 | 1.31B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
How Investors May Respond To Harrow (HROW) Issuing US$50M In 8.625% Senior Notes For Growth - simplywall.st
Harrow announces $50M add-on senior notes offering - MSN
Fundamentals Check: Is Harrow Inc attractive for institutional investorsNew Guidance & Smart Investment Allocation Tips - baoquankhu1.vn
A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal? - AOL.com
Harrow prices $50M senior unsecured notes due 2030 at 8.625% - MSN
Harrow Health Prices $50 Million Senior Notes Offering - TipRanks
Harrow (NASDAQ: HROW) adds $50M to 8.625% 2030 senior notes - Stock Titan
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030 - GlobeNewswire
Harrow Announces $50 Million Add-On Offering of 8.625% Senior Unsecured Notes Due 2030 to Support Growth - Minichart
A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal? - The Motley Fool
Harrow to Issue Additional $50 Million Debt Offering - marketscreener.com
Harrow Health Announces $50 Million Senior Notes Offering - TipRanks
Harrow launches $50.0M add-on 8.625% senior notes due 2030 for growth initiatives - TradingView
Harrow (NASDAQ: HROW) plans $50M add-on 8.625% 2030 note issue - Stock Titan
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth - GlobeNewswire
MongoDB, Surgery Partners, Harrow and other big stocks moving lower in Tuesday's pre-market session - MSN
EnerQuest Technologies Solutions Inc.’s Harrow facility undergoes $15.8M expansion - constructconnect.com
Harrow Health Inc stock faces valuation scrutiny amid eye care expansion push - AD HOC NEWS
HROW Stock Price, Quote & Chart | HARROW INC (NASDAQ:HROW) - ChartMill
HROW: Analyst HC Wainwright & Co. Reiterates 'Buy' with $70 Targ - GuruFocus
Harrow's (HROW) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Harrow (HROW) to Release Quarterly Earnings on Thursday - MarketBeat
Nomura Downgrades Harrow Health, Inc. (HROW) to Neutral March 18, 2026 - Meyka
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting - Bitget
Harrow outlines $350M–$365M 2026 revenue goal as sales force expansion and pipeline advances fuel momentum - MSN
HROW: BTIG Reiterates Buy Rating with $63 Price Target | HROW St - GuruFocus
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - MarketBeat
Penn Capital Management Company LLC Makes New Investment in Harrow, Inc. $HROW - MarketBeat
EnerQuest expansion in Essex County to bring jobs, shift production from U.S. - CBC
Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market (NASDAQ:HROW) - Seeking Alpha
Cantor Fitzgerald Initiates Coverage of Harrow (HROW) with Overweight Recommendation - MSN
EnerQuest in Harrow gets support for re-shoring manufacturing - Sarnia News Today
307,337 Shares in Harrow, Inc. $HROW Bought by Luxor Capital Group LP - MarketBeat
Harrow: why this fast-growing eye-care pharma stock is worth a look - Finimize
Braidwell LP Decreases Stock Position in Harrow, Inc. $HROW - MarketBeat
Assessing Harrow (HROW) Valuation After Strong Revenue Growth And TRIESENCE Phase 3 Progress - Sahm
Harrow, Inc. (NASDAQ:HROW) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3 - simplywall.st
Daniel Kaufman holds 1.878M Harrow shares (HROW) — 5.04% reported - Stock Titan
Harrow Health Projects Robust Growth After Strong 2025 - The Globe and Mail
Harrow Health at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Harrow (HROW) Q4 2025 Earnings Call Transcript - AOL.com
HROW: Record growth and expanding ophthalmic portfolio drive optimism for future launches - TradingView
Harrow (NASDAQ: HROW) furnishes March 2026 corporate investor presentation - Stock Titan
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions - Investing.com Canada
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Reven - GuruFocus
HARROW INCHROW 8 5/8 04/30/26 (HROWL) Earnings History & Surprises - ChartMill
Is Harrow Inc. stock a top pick in earnings seasonTrade Performance Summary & Safe Entry Point Alerts - Naître et grandir
Harrow, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:HROW) 2026-03-06 - Seeking Alpha
Has The Recent Slide In Harrow (HROW) Opened A Valuation Opportunity For Investors - simplywall.st
HC Wainwright Issues Negative Forecast for Harrow Earnings - MarketBeat
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):